Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.
Beam Therapeutics got good early results from testing a new medicine to fix a rare disease. This kind of progress is what companies need to show the FDA (the government group that approves medicines) they're on the right track.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.